Kate Therapeutics
Eric Wang is the Co-Founder of Kate Therapeutics and currently serves as an Associate Professor at the University of Florida. Prior to this, Eric was a Principal Investigator at the Koch Institute for Integrative Cancer Research at MIT. Eric holds a Ph.D. in Bioinformatics and Integrative Genomics from the Harvard-MIT Division of Health Sciences and Technology.
This person is not in the org chart
This person is not in any offices
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.